Hermed Capital

Hinova Pharmaceuticals Inc. is a drug discovery and development company based in Chengdu, China, with additional branches in Hong Kong, Texas, and Australia. Established in 2013, the company specializes in the research and manufacturing of innovative medicines to address unmet medical needs, particularly in oncology and metabolic diseases. Utilizing advanced technology platforms such as deuterium and PROTAC, Hinova develops both Best-in-class and First-in-class drugs. Its product pipeline includes the HC-1119 androgen receptor antagonist and HC-1102 androgen receptor inhibitors, which target advanced prostate cancer and breast cancer. The company's commitment lies in providing safe, effective, and affordable treatments while retaining global rights and interests in its drug portfolio.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Spineology Inc. is a medical device company specializing in anatomy-conserving technology solutions for spine surgery. Founded in 1996 and headquartered in Saint Paul, Minnesota, the company offers a range of products designed to enhance surgical efficiency and improve patient outcomes. Its product lineup includes pedicular fixation systems like Threshold and Fortress, interbody fusion solutions such as Duo and Rampart, and biologics like the Prime liquid tissue matrix and Armor amniotic wound covering. Additionally, Spineology provides a variety of surgical instruments, including the Capture facet fixation system, VIA spinous process fixation system, and Medius midline retractor system, among others. The company focuses on using minimally invasive techniques to reduce post-operative pain and facilitate quicker recovery for patients suffering from spinal-related issues.

Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Minneapolis, Minnesota, dedicated to developing innovative treatments for kidney and neurological diseases. The company's lead drug candidate, DM199, is a recombinant human tissue kallikrein-1 protein. It has completed Phase Ib clinical trials for treating moderate to severe chronic kidney disease linked to Type I or Type II diabetes and is undergoing Phase II trials for acute ischemic stroke. DM199 has been administered to nearly 100 patients, demonstrating a safe and well-tolerated profile. Additionally, DiaMedica is developing DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. The company has a collaboration agreement with Ahon Pharmaceutical Co Ltd. to further develop and commercialize DM199 for acute ischemic stroke. DiaMedica Therapeutics was founded in 2000 and was previously known as DiaMedica Inc. before rebranding in December 2016.

Applied StemCell Inc. is a biotechnology company specializing in the development of animal and cell line models for drug discovery and diagnostics. The company utilizes its proprietary TARGATT™ gene modification technology to create site-specific Knockin mouse, rat, and human cell line models, making the process efficient for both pharmaceutical and academic researchers. Applied StemCell's offerings include a range of genetically modified models, such as Knockin, Knockout, and transgenic mice, as well as humanized mouse models and gene-modified induced pluripotent stem cells (iPSCs). In addition to model development, the company provides optimized stem cell culture products and gene engineering services for mammalian cells. By continuously enhancing its technologies and product lines, Applied StemCell aims to meet the evolving needs of the biomedical community and support advancements in molecular diagnostics and personalized medicine.

Ativa Medical Corporation is a medical device manufacturing company based in Saint Paul, Minnesota, founded in 2008. The company specializes in developing and commercializing point of care testing medical diagnostics products aimed at decentralized healthcare settings. Ativa Medical focuses on providing rapid diagnostic test results for critical hematology and clinical chemistry tests, utilizing advanced microfluidics technology. Its product offerings include analyzers and disposable test cards designed for trauma, pediatric, oncology, and geriatric patients. These products cater to various healthcare environments, including hospital departments, physician's offices, and remote healthcare clinics, enhancing the speed and accessibility of medical diagnostics.